2014
DOI: 10.1200/jco.2014.32.15_suppl.tps6106
|View full text |Cite
|
Sign up to set email alerts
|

PAZOTHYR: A randomized, multicenter, open-label, phase II study of the optimal scheme of pazopanib in radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC).

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles